Standard BioTools Inc. Amortization of Debt Issuance Costs and Discounts
Standard BioTools Inc. (LAB) reported Amortization of Debt Issuance Costs and Discounts of $770.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2024-03-01
- Standard BioTools Inc. amortization of debt issuance costs and discounts for the quarter ending 2023-12-31 was $173.00K, a 14.36% decline year-over-year.
- Standard BioTools Inc. amortization of debt issuance costs and discounts for the quarter ending 2023-09-30 was $187.00K, a 8.78% decline year-over-year.
- Standard BioTools Inc. amortization of debt issuance costs and discounts for the quarter ending 2023-06-30 was $206.00K, a 2.83% decline year-over-year.
- Standard BioTools Inc. amortization of debt issuance costs and discounts for the quarter ending 2023-03-31 was $204.00K, a 3.32% decline year-over-year.
- Standard BioTools Inc. amortization of debt issuance costs and discounts for fiscal 2023 was $770.00K, a 7.23% decline from fiscal 2022.
- Standard BioTools Inc. amortization of debt issuance costs and discounts for fiscal 2022 was $830.00K, a 33.01% increase from fiscal 2021.
- Standard BioTools Inc. amortization of debt issuance costs and discounts for fiscal 2021 was $624.00K, a 14.50% increase from fiscal 2020.
- Standard BioTools Inc. amortization of debt issuance costs and discounts for fiscal 2020 was $545.00K, a 71.85% decline from fiscal 2019.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2023-12-31 | $173.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $360.00K derived: sum of 2 quarters · filed 2024-03-01 | $566.00K derived: sum of 3 quarters · filed 2024-03-01 | $770.00K 10-K · filed 2024-03-01 |
| 2023-09-30 | $187.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $393.00K derived: sum of 2 quarters · filed 2023-11-07 | $597.00K 10-Q · filed 2023-11-07 | $799.00K derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-06-30 | $206.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $410.00K 10-Q · filed 2023-08-08 | $612.00K derived: sum of 3 quarters · filed 2024-03-01 | $817.00K derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-03-31 | $204.00K 10-Q · filed 2023-05-09 | $406.00K derived: sum of 2 quarters · filed 2024-03-01 | $611.00K derived: sum of 3 quarters · filed 2024-03-01 | $823.00K derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-12-31 | $202.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $407.00K derived: sum of 2 quarters · filed 2024-03-01 | $619.00K derived: sum of 3 quarters · filed 2024-03-01 | $830.00K 10-K · filed 2024-03-01 |
| 2022-09-30 | $205.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $417.00K derived: sum of 2 quarters · filed 2023-11-07 | $628.00K 10-Q · filed 2023-11-07 | $825.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $212.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $423.00K 10-Q · filed 2023-08-08 | $620.00K derived: sum of 3 quarters · filed 2023-08-08 | $836.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $211.00K 10-Q · filed 2023-05-09 | $408.00K derived: sum of 2 quarters · filed 2023-05-09 | $624.00K derived: sum of 3 quarters · filed 2023-05-09 | $703.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $413.00K derived: sum of 2 quarters · filed 2023-03-14 | $492.00K derived: sum of 3 quarters · filed 2023-03-14 | $624.00K 10-K · filed 2023-03-14 |
| 2021-09-30 | $216.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $295.00K derived: sum of 2 quarters · filed 2022-11-09 | $427.00K 10-Q · filed 2022-11-09 | $557.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $211.00K 10-Q · filed 2022-08-09 | $341.00K derived: sum of 3 quarters · filed 2022-08-09 | $481.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $132.00K 10-Q · filed 2022-05-09 | $262.00K derived: sum of 2 quarters · filed 2022-05-09 | $402.00K derived: sum of 3 quarters · filed 2022-05-09 | $537.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $270.00K derived: sum of 2 quarters · filed 2022-03-08 | $405.00K derived: sum of 3 quarters · filed 2022-03-08 | $545.00K 10-K · filed 2022-03-08 |
| 2020-09-30 | $140.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $275.00K derived: sum of 2 quarters · filed 2021-11-09 | $415.00K 10-Q · filed 2021-11-09 | $221.00K derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | $135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $275.00K 10-Q · filed 2021-08-06 | $81.00K derived: sum of 3 quarters · filed 2022-03-08 | $174.00K derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | $140.00K 10-Q · filed 2021-05-07 | -$54.00K derived: sum of 2 quarters · filed 2022-03-08 | $39.00K derived: sum of 3 quarters · filed 2022-03-08 | $39.00K derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | -$194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$101.00K derived: sum of 2 quarters · filed 2022-03-08 | -$101.00K derived: sum of 3 quarters · filed 2022-03-08 | $1.94M 10-K · filed 2022-03-08 |
| 2019-09-30 | $93.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $93.00K derived: sum of 2 quarters · filed 2020-11-09 | $2.13M 10-Q · filed 2020-11-09 | $4.79M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $2.04M 10-Q · filed 2020-08-07 | $4.70M derived: sum of 3 quarters · filed 2021-02-25 | $7.33M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $2.04M 10-Q · filed 2020-05-11 | $4.70M derived: sum of 2 quarters · filed 2021-02-25 | $7.33M derived: sum of 3 quarters · filed 2021-02-25 | $9.91M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $5.30M derived: sum of 2 quarters · filed 2021-02-25 | $7.87M derived: sum of 3 quarters · filed 2021-02-25 | $8.38M 10-K · filed 2021-02-25 |
| 2018-09-30 | $2.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $5.21M derived: sum of 2 quarters · filed 2019-11-08 | $5.71M 10-Q · filed 2019-11-08 | $5.76M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $3.08M 10-Q · filed 2019-08-07 | $3.13M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2018-03-31 | $505.00K 10-Q · filed 2019-05-07 | $550.00K derived: sum of 2 quarters · filed 2020-02-27 | ||
| 2017-12-31 | $45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $287.00K 10-K · filed 2020-02-27 | ||
| 2017-09-30 | $242.00K 10-Q · filed 2018-11-06 | |||
| 2016-12-31 | $278.00K 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |